CHINA LEX PHARMA LAW NEWSLETTER
Vol. 3 , No.4 - February 21, 2002
TOPICS THIS ISSUE:
- Viagra Prescription Restrictions Lifted
- China Sums Up a Year Working Against Counterfeit Drugs
- Health Canada Warns Public to not use China-Manufactured Hua
Fo
- Blood Industry Will Receive US $270 Million to Ensure Safe Donations
- China's WTO Commitments Likely to Attract Many Foreign Hospitals
- International SOS Excited about the Mainland Market
- Shanghai Hospitals Open to Foreign and Private Funding
- List of China GMP Facilities (Continued)
Viagra Prescription Restrictions Lifted
Patients are now able to obtain Viagra prescriptions from more
doctors, due to the recent lifting of restrictions on doctors issuing
prescriptions for males with erectile dysfunction (ED).
The State Drug Administration, together with the Ministry of Health,
announced that chief physicians, from second-class hospitals up,
in cardiovascular, endocrine, psychosurgery and internal medicine
for neuropathy departments are now permitted to write prescriptions
for Viagra. Before the joint statement, only senior physicians specializing
in urology were authorized to issue prescriptions for the controversial
drug.
Viagra, which entered the Mainland Chinese market in July 2000,
obtained patent approval in September of 2001.
(Source: Xinhua News Agency)
China Sums Up a Year Working Against Counterfeit Drugs
In a recent conference, the State Drug Administration announced
that 2001 was a productive year regarding the control of counterfeit
medicines.
Zheng Xiaoyu, director of the SDA, said that in 2001, the SDA was
involved in approximately 51,700 cases dealing with the manufacturing
and sale of counterfeit medicines. The cases amounted to RMB 485
million (US $58.4 million).
Although Zheng warned of the danger of fake drugs, it is a surprise
that only 269 of those cases resulted in criminal charges. Zheng
said "the fakes are very dangerous and pose a threat to public health."
The SDA also reported that they confiscated more than 150,000 dosages
of expired medicines worth RMB 229 million (US $27.6 million) and
looked into 2, 337 cases of counterfeit or defective medical equipment.
Zheng also noted that they found "256 firms that had reworked animal
medicines for human use."
Despite the low number of criminal charges, the crackdown has not
left the manufacturers of counterfeit medicines unharmed. The SDA
director reported that the number of wholesale pharmaceutical firms
decreased by 27%. In the latest round of recertification, 2, 660
manufacturers of medical equipment were removed from the market,
225 pharmaceutical firms were ordered to reorganize and improve,
779 applications were rejected and 6, 731 licenses were granted.
The latest round of revocations will not be the last either. Li
Hongsheng, the State Drug Administration's Market Compliance Department
Head, said "due to legislative amendments, pharmaceutical companies
unable to meet the new quality standards by 2004 will be wiped out."
Due to the high percentage of patients reporting adverse reactions
to prescribed drugs, a nationwide network to monitor the adverse
effects has been formed. Presently, 10 to 30 per cent of the patients
in hospitals report adverse reactions to drugs prescribed.
Now, not only hospitals must report any adverse reactions, but
also drugmakers, medical equipment manufacturers and distributors
must also report any suspected adverse reactions. Last year, over
7, 500 reports were filed.
Zheng said "A long-term campaign against the illegal pharmaceutical
trade will help the pharmaceutical sector move along a sound track,
guarantee people's health and provide a good investment environment
for drugmakers."
Although many fines are still too low, such as RMB 30,000 (US $
3,610) for concealing any adverse drug reactions, and the criminal
charges too few, SDA officials remain optimistic. Zheng said "Last
year, we rolled out the new Drug Management Law, providing specific
and tough penalties for violations. We will continue to make the
legislation more transparent and consistent."
(Source: Business Daily Update)
Health Canada Warns Public to not use China-Manufactured Hua Fo
Health Canada has issued a warning to consumers, health care professionals
and provincial health ministries to not use Hua Fo tablets, an unapproved
herbal product manufactured in China that claims to enhance sexual
function.
Health Canada analyzed samples of Hua Fo tablets and found that
they contained sildenafil. Sildenafil is the drug approved as prescription
only for male erectile dysfunction, sold under the brand name Viagra.
Use of sildenafil without medical supervision can cause severe adverse
reactions.
Concurrent use of Sildenafil with nitrate medications can result
in the development of potentially life-threatening low blood pressure
and in some cases result in penile tissue damage and permanent loss
of potency.
Although there have been no adverse drug reactions reported yet,
Health Canada is advising consumers who have used Hua Fo to contact
their physicians.
Health Canada reported that they are working with the importer
of the unapproved product, Shenlong Company, to remove it off the
market.
Hua Fo is manufactured in China by Guizhou Ribulo Medical Industry
Inc.
(Source: Canada Newswire)
Profitable
China GMP Facility for Sale
Send email to mail@chinalaw.cc
for further information.
|
Blood Industry Will Receive US $270 Million to Ensure Safe Donations
RMB 2.25 billion (US $270 million) will be spent on China's blood
banks in an effort to stop the spread of hepatitis and AIDS through
tainted blood.
It is planned that the influx of investment will allow blood banks
to modernize their equipment and test all blood for the HIV virus.
Fourteen firms, both Chinese and overseas, signed contracts recently
to provide RMB 396 million worth of equipment and vehicles to blood
stations.
The Ministry of Health reported that it estimates 30, 000 - 50,
000 people were infected with HIV through selling blood to illegal
blood banks in the 90s. However, some reports have put the real
number as high as 700,000 in the central province of Henan alone.
There are currently 10,000 hospitals and 300 blood stations offering
blood transfusions in China. The government promised last year to
close all illegal blood stations and establish safe networks for
blood donations.
Although government officials aim to keep the number of HIV carriers
below 1.5 million by 2010, the United Nations has said that infections
could be as high as 10 million in 10 years.
(Source: Deutsche Presse-Agentur)
China's WTO Commitments Likely to Attract Many Foreign Hospitals
According to China's commitments in entering WTO, the medical service
industry will be opened up and foreign parties will be allowed to
cooperate with Chinese parties in establishing co-invested or cooperative
hospitals and clinics.
The industry will be formally opened in 2003, which will almost
certainly mean a surge of large-scale foreign hospitals entering
the domestic medical service market.
So far, there are only roughly 200 cooperative medical centers
in China, and the majority are small and cater to foreigners.
According to the commitments, the investment of the co-invested
or cooperative medical ventures cannot be less than RMB 20 million
and must have at least 100 beds.
It is predicted that the mass introduction of foreign hospitals
will lead to new styles of management and operations for domestic
medical organs.
(Source: Asiainfo)
International SOS Excited about the Mainland Market
International SOS has stated it will increase its presence in China
and strengthen its co-operation with local hospitals.
China's accession into the World Trade Organization (WTO) has brought
more opportunities for the world's service businesses, among which
medical help is a considerable portion.
International SOS, which started its business in China in 1989,
is trying to expand its service network to better cater to the needs
of increasing numbers of foreigners coming into the country as well
as Chinese seeking better medical services. "China's WTO entry means
a big increase in foreign investment, and more companies will send
staff here," said Arnaud Vaissie, company president. "The need for
emergency assistance will rise sharply." Other overseas medical
companies are also squeezing into the growing market. There are
more than a dozen clinics in Beijing with overseas investment. Nationwide,
the number has reached nearly 200, according to official statistics.
Although most of their clients are foreigners, an increasing number
of local Chinese, not satisfied with domestic medical services,
are seeking help from these agencies, creating a huge potential
market.
Vaissie said his company is planning an alarm center in Kunming,
the capital of Southwest China's Yunnan Province, to bolster its
service capacity in the country's western region.
The company has already set up three 24-hour alarm centers in Beijing,
Shanghai and Hong Kong and opened clinics in Beijing, Tianjin, Nanjing,
Guangzhou and Taipei.
It also has established co-operative relationships with more than
150 major hospitals across China.
"Even if a client of ours is in a remote area such as Tibet, he
or she can have convenient access to medical treatment in our local
co-operative hospitals there," he said.
The company wants its clients to get a better understanding of
China's medical system, "which is now quite sound," said He Jingbin,
deputy general manager of International SOS' Beijing clinic.
One of the company's partners in Beijing is the Sino-Japanese Friendship
Hospital, which receives more than 500 patients a year from the
International SOS's Beijing clinic.
"Our hospital can offer technical support to the SOS clinic since
it is hard for the clinic to carry out systematic and complicated
treatment," said Yan Xiangjian, deputy director of the hospital's
medical affairs department.
(Source: China Daily)
Shanghai Hospitals Open to Foreign and Private Funding
The funding pattern of hospitals is changing in Shanghai. According
to sources at a meeting held in Shanghai on Wednesday, private and
foreign investment will be permitted.
Officials from the Shanghai Municipal Health Bureau said that various
financial channels will be opened and that future financial support
will come from government, private and foreign sources.
The officials also said that an investment company and a state
asset management company will be established by the local government
to manage the financing and administration of local hospitals.
However, it is only on condition that the services at public non-profit
hospitals do not suffer that the local health services market will
be opened up to private and foreign investors.
(Source: Xinhua News Agency)
|
China
Pharma Distribution Company for Sale
Send email to mail@chinalaw.cc
for further information.
|
List of China GMP Facilities (Continued)
|
Name of Enterprise
|
Certified Scope
|
| 701. Chengdu Bio-products Research
Institute |
Blood products |
| 702. Dangshan Huakai Bio-tech Union
Co., Ltd. |
Blood products |
| 703. Beijing Tiantan Bio-products
Co., Ltd. by shares |
Blood products |
| 704. Harbin Shiheng Bio-engineering
Pharma Co., Ltd. |
Blood products |
| 705. Shanghai Laishi Blood Product
Co., Ltd. |
Blood products |
| 706. Lanzhou Bio-products Research
Institute |
Blood products |
| 707. Shanghai Bio-products Research
Institute |
Blood products |
| 708. Jinan Army Bio-products Pharma
Research Institute |
Blood products |
| 709. Wuhan Reide Bio-products Co.,
Ltd. |
Blood products |
| 710. Shanxi Kangbao Bio-products
Co., Ltd. by shares |
Blood products |
| 711. Chengdu Shuyang Pharma Factory
|
Blood products |
| 712. Wuhan Bio-products Research
Institute |
Blood products |
| 713. Xian Huitian Blood Products
Co., Ltd. |
Blood products |
| 714. Xinjiang Haosida Bio-products
Co., Ltd. |
Blood products |
| 715. Shenzhen Weiwu Guangming Bio-products
Factory |
Blood products |
| 716. Zhengzhou Haixing Banghe Bio-pharma
Co., Ltd. |
Blood products |
| 717. Guiyang Qianfeng Bio-products
Co., Ltd. |
Blood products |
| 718. Shantou Weilun Bio-products
Co. |
Blood products |
| 719. Liaoning Liaoyang Blood Technology
Co., Ltd. |
Blood products |
| 720. Chongqing Jianxin Blood Product
Co., Ltd. |
Blood products |
| 721. Shandong Bio-products Research
Institute |
Blood products |
| 722. Jiangsu Huaning Bio-products
Co., Ltd. |
Blood products |
| 723. Zhejiang Haikang Bio-products
Co., Ltd. |
Blood products |
| 724. Guangdong Blood Products Institute
|
Blood products |
| 725. Hengyang Nanyang Pharma Factory
|
Blood products |
| 726. Zhanjiang Shuanglin Pharma Co.,
Ltd. |
Blood products |
| 727. Shanghai Xinxing Blood Products
Research Institute |
Blood products |
| 728. Guangxi Bio-products Research
Institute |
Blood products |
| 729. Chengdu Kanghong Pharma Co.,
Ltd. |
Blood products |
| 730. Jiangxi Puzhong Pharma Co.,
Ltd. |
Capsule |
| 731. Tianjin Hexal Pharma Co., Ltd.
|
Tablet |
| 732. Zhuhai Economic Special Zone
Bio-chemical Pharma Factory |
Tablet |
| 733. Baoding Sanjiu Jishi Bio-pharma
Co., Ltd. |
Injection |
| 734. Hebei Huari Pharma Co., Ltd.
|
Bulk |
| 735. Huaxi Medical University Pharma
Factory |
Granule |
| 736. Shanghai Squibb Pharma Co.,
Ltd. |
Tablet, Liquid preparation, Cream
|
| 737. Guangzhou Beishi Pharma Co.,
Ltd. |
Tablet, Capsule |
| 738. Shandong Lukang Pharma Group
Luyuan Co. |
Powder-injection |
| 739. Shandong Lukang Pharma Group
Luyuan Co. |
Oral solid preparations |
| 740. Shandong Lukang Chenxin Pharma
Co. |
Injection |
| 741. Shandong Lukang Chenxin Pharma
Co. |
Injection |
| 742. Shandong Lukang Pharma Group
Luya Co. |
Freeze-dried powder-injection |
| 743. Anhui Anke Biology High-tech
Co., Ltd. |
Recombinant human interferon workshop
|
| 744. Anhui Anke Biology High-tech
Co., Ltd. |
Recombinant human interferon workshop
|
| 745. Zhuhai Shwarz Pharma Co., Ltd.
|
Tablet, Capsule |
| 746. Shenzhen Zhonglian Pharma Factory
|
Tablet, Capsule |
| 747. Weihai Aiwei Pharma Co., Ltd.
|
High dose injection |
| 748. Zibo Wanjie Pharma Co., Ltd.
|
Tablet, Capsule |
| 749. Changchun Bio-products Research
Institute |
Blood products |
| 750. Shandong Lukang Pharma Group
LuyuanCo. |
Bulk |
Lehman
Lee & Xu
China Lawyers, Notaries, Patent, Copyright and Trademark Agents
http://www.chinalaw.cc/
|
Beijing Office
|
Shanghai Office
|
|
6th floor, Dongwai Diplomatic Office Building
23 Dongzhimenwai Dajie
Beijing 100600 China
Tel.: (86)(10) 8532-1919
Fax: (86)(10) 8532-1999
Email: mail@chinalaw.cc
|
Suite 5107, Plaza 66
No. 1266, West Nanjing Road
Shanghai 200040 China
Tel: (86)(21) 6375-8240
Fax:(86)(21) 6375-8705
Email: shanghai@chinalaw.cc
|
To unsubscribe from this newsletter send an email to unsubscribe_lp@chinalaw.cc
Please include the email address to which the newsletter is
being sent (not a forwarded address) in the body of the email.
|